Join Capital Cell at its Medtech investor evening
2015-16 saw a third consecutive year of venture capital financing growth in Medtech, with a record $5.6 billion raised globally (Ref: EY Medtech report 2016). European Medtech companies enjoyed 12% growth in financing in the same period.
Join Capital Cell’s Medtech investor evening on November 16th in London for the chance to hear four Medtech companies screened by Capital Cell pitching for investment- all have existing revenues or have been granted regulatory approval to enter at least one market.
In addition to pitches, the evening will feature a keynote talk on innovation and investment in the sector.
18:30 Welcome,Keynote talk
19:00 4 company presentations
20:00 Networking with drinks
This event is only open to registered users of the Capital Cell platform, if you are not already registered, please sign up at www.capitalcell.co.uk.
Equity investment though Capital Cell starts at £300.
For more details on the companies pitching or investing through Capital Cell, please contact the UK Head of Research, Jack Brownrigg: firstname.lastname@example.org
Your capital is at risk. Investing in early stage companies involves risks including loss of capital, illiquidity, lack of dividends and dilution. The availability of tax relief (such as EIS) depends on individual investors’ circumstances, and on investee companies’ qualifying status, both of which may be subject to change.
Capital Cell Ltd (FRN 774677) is an Appointed Representative of Larpent Newton & Co Ltd. This message has been approved as a financial promotion by Larpent Newton & Company Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN: 141275). Investments are only offered to Capital Cell registered users.
To read more information, click here.
Capital Cell is Europe’s first equity crowdfunding platform specialised in life science.